Key result
Long-term oral anticoagulation prevents recurrent thrombosis in antiphospholipid syndrome, but immunosuppression provides no benefit.
Answers are grounded in this paper and cite their sources.
Optimal management of patients with the antiphospholipid syndrome (APS) remains a problem. There is now good evidence that those with thrombosis will be subject to recurrences and require long-term, possibly lifelong, oral anticoagulation. Steroids and immunosuppressive drugs aiming at a reduction of the antibody levels have not provided long-term benefit. Only prospective and controlled clinical trials can give a definitive answer to the optimal thrombotic prophylaxis in patients with the APS.
No takes yet. Share an insight, caveat, or question.
MA Khamashta (1996) conducted a review in Antiphospholipid syndrome with thrombosis. Long-term oral anticoagulation vs. Steroids and immunosuppressive drugs was evaluated on Thrombotic recurrence. Long-term oral anticoagulation is required to prevent recurrent thrombosis in antiphospholipid syndrome, whereas steroids and immunosuppressants show no long-term benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: